New pill shows promise in early trial for Hard-to-Treat cancers

NCT ID NCT06212076

Recruiting now Disease control Sponsor: Nanjing Immunophage Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new drug called IPG1094 in 60 people with advanced solid tumors that cannot be removed by surgery. The drug works by blocking a protein called MIF, which may help slow cancer growth. The trial has two parts: first, finding the safest dose, then seeing if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IPG1094 (a MIF inhibitor tablet)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early phase 1/2 trial with only 60 participants, so it is too soon to know if IPG1094 is safe or effective. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Shanghai General Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200080, China
Shanghai GoBroad Cancer Hospital China Pharmaceutical University
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.